Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.

Edmund LauEugene KotlyarYogeshwar MakanjiDae Young YuJin Yu TanJeremy CasorsoMahsa H KouhkamariSooyeol LimDavid Bin-Chia WuPaul Bloomfield

Published in: Journal of medical economics (2024)

Real-world data for Australian patients with PAH showed that treatment adherence for ERAs was suboptimal. Adherence was higher for macitentan compared with ambrisentan and bosentan.

Keyphrases

pulmonary arterial hypertension
pulmonary artery
pulmonary hypertension
glycemic control
type diabetes
deep learning
combination therapy
adverse drug